Litcius/Paper detail

Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT

Raúl D. Santos, Andrea Ruzza, G. Kees Hovingh, Claudia Stefanutti, François Mach, Olivier Descamps, Jean Bergeron, Bei Wang, Andrea Bartuli, Paola Sabrina Buonuomo, Susanne Greber‐Platzer, Ilse K. Luirink, Ajay Bhatia, Frederick J. Raal, John J.P. Kastelein, Albert Wiegman, Daniel Gaudet

2022The Lancet Diabetes & Endocrinology48 citationsDOIOpen Access PDF

Topics & Concepts

MedicineEvolocumabPlaceboAdverse effectRandomized controlled trialClinical endpointInternal medicinePopulationCholesterolLipoproteinPathologyApolipoprotein A1Alternative medicineEnvironmental healthLipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismInflammatory Bowel Disease
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT | Litcius